Country Club Bank Lowers Stock Position in Johnson & Johnson $JNJ

Key Points

• Country Club Bank reduced its stake in Johnson & Johnson by 1.6% in the second quarter, holding a total of 107,683 shares valued at approximately $16.4 million.
• Johnson & Johnson reported earnings of $2.77 per share for the latest quarter, surpassing analysts' estimates, with revenue reaching $23.74 billion, up 5.8% year-over-year.
• The company declared a quarterly dividend of $1.30 per share, representing an annualized dividend of $5.20 and a yield of 2.7%.

Country Club Bank cut its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 107,683 shares of the company's stock after selling 1,737 shares during the period. Johnson & Johnson accounts for 1.0% of Country Club Bank's holdings, making the stock its 21st biggest position. Country Club Bank's holdings in Johnson & Johnson were worth $16,412,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in JNJ. Highline Wealth Partners LLC grew its stake in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the 1st quarter valued at $47,000. 1248 Management LLC acquired a new stake in Johnson & Johnson in the 1st quarter valued at $48,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson in the 1st quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson in the 1st quarter valued at $52,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ opened at $189.75 on Thursday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $190.22. The stock has a market cap of $456.98 billion, a PE ratio of 20.29, a P/E/G ratio of 2.41 and a beta of 0.40. The firm has a 50-day simple moving average of $177.49 and a two-hundred day simple moving average of $163.37. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period last year, the business earned $2.82 earnings per share. The business's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on JNJ shares. Weiss Ratings raised shares of Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday. HSBC lifted their price target on shares of Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Bank of America lifted their target price on shares of Johnson & Johnson from $175.00 to $198.00 and gave the stock a "neutral" rating in a research note on Friday, October 3rd. Guggenheim raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the stock an "overweight" rating in a research note on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $189.88.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.